Research and
education
deserve attention.

Which is just
what we create.

Client's-News

23. April 2019

AD HOC ANNOUNCEMENT Marinomed Biotech AG announces top line results of the Phase III study for Budesolv:

Marinomed Biotech AG, a globally active biopharmaceutical company with headquarters in Vienna, has announced the successful completion of the pivotal Phase III study for Budesolv. The top line results are now available and show that Budesolv achieves at least the same effect as the product which is currently on the market, with a significantly lower dose.

read more

Client's-News

11. April 2019

Health centres for the homeless: evaluation requires trust:

Trust is a vital factor when it comes to evaluating health centres for socially disadvantaged people. This is a basic recommendation of the Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA) in Vienna (Austria), which has published the results of a large-scale international study of this topic.

read more

 
Latest news from Facebook Facebook
Upcoming Events

AM PULS Nr. 64

Designer Babies, Mammoths & Co. –

The Possibilities of Synthetic Biology

 

(in German only)

 

ap-schriftzug

Wednesday, 3th April 2019 • 6 pm

Kunden-News

23. April 2019

AD HOC ANNOUNCEMENT Marinomed Biotech AG announces top line results of the Phase III study for Budesolv:

Marinomed Biotech AG, a globally active biopharmaceutical company with headquarters in Vienna, has announced the successful completion of the pivotal Phase III study for Budesolv. The top line results are now available and show that Budesolv achieves at least the same effect as the product which is currently on the market, with a significantly lower dose.

News lesen

Kunden-News

11. April 2019

Health centres for the homeless: evaluation requires trust:

Trust is a vital factor when it comes to evaluating health centres for socially disadvantaged people. This is a basic recommendation of the Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA) in Vienna (Austria), which has published the results of a large-scale international study of this topic.

News lesen

Kunden-News

26. February 2019

Marinomed receives EUR 15m EIB financing:

The European Investment Bank (EIB) is providing EUR 15m to Marinomed Biotech AG, a Vienna- based biopharmaceutical company developing innovative therapies for allergy, respiratory and eye diseases

News lesen

Kunden-News

20. February 2019

Heavy Metals Weigh on Unborn Babies’ Health:

Researchers from Karl Landsteiner University of Health Sciences (Austria) and the Medical University of Vienna explain workings of placental transport systems; spotlight on mercury and iron.

News lesen

Kunden-News

23. January 2019

Marinomed: Partnership in China and EIB Financing:

Marinomed Biotech AG, an established biopharmaceutical company creating innovative therapies for allergy, respiratory and eye diseases, achieved significant strategic milestones and operational success in the first weeks of 2019.

News lesen